Daymark Wealth Partners LLC Sells 279 Shares of Bristol-Myers Squibb (NYSE:BMY)

Daymark Wealth Partners LLC cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,685 shares of the biopharmaceutical company’s stock after selling 279 shares during the period. Daymark Wealth Partners LLC’s holdings in Bristol-Myers Squibb were worth $4,738,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. LaFleur & Godfrey LLC grew its stake in shares of Bristol-Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 1,487 shares in the last quarter. Brighton Jones LLC lifted its holdings in shares of Bristol-Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Silver Oak Securities Incorporated grew its position in Bristol-Myers Squibb by 76.4% in the fourth quarter. Silver Oak Securities Incorporated now owns 6,997 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 3,030 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter worth about $4,377,000. Finally, Golden State Wealth Management LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $199,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Trading Up 1.2%

NYSE BMY opened at $48.42 on Monday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market capitalization of $98.54 billion, a price-to-earnings ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The company’s 50-day simple moving average is $49.34 and its two-hundred day simple moving average is $55.02.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue was down 5.6% compared to the same quarter last year. During the same period last year, the company posted ($4.40) earnings per share. Equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMY. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group lowered their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.